

# Annamaria Colao

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/950476/annamaria-colao-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

410  
papers

16,216  
citations

66  
h-index

109  
g-index

442  
ext. papers

19,542  
ext. citations

6  
avg, IF

6.78  
L-index

#	Paper	IF	Citations
410	Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition.. <i>International Journal of Obesity</i> , <b>2022</b> ,	5.5	8
409	Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1	5.2	1
408	Obesity and Thyroid Cancer Risk: An Update.. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19,	4.6	1
407	Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 45, 849	5.2	3
406	Sarcopenic obesity: What about in the cancer setting?. <i>Nutrition</i> , <b>2022</b> , 98, 111624	4.8	1
405	VLCKD: a real time safety study in obesity.. <i>Journal of Translational Medicine</i> , <b>2022</b> , 20, 23	8.5	3
404	Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome?. <i>Nutrients</i> , <b>2022</b> , 14,	6.7	3
403	L'ambulatorio di Endocrinologia durante e dopo la pandemia da COVID-19: opinioni e riflessioni. <i>L'Endocrinologo</i> , <b>2022</b> , 23, 119-124	0	
402	Prognostic significance of laterality in lung neuroendocrine tumors.. <i>Endocrine</i> , <b>2022</b> , 1	4	0
401	Dietary Recommendations for Post-COVID-19 Syndrome.. <i>Nutrients</i> , <b>2022</b> , 14,	6.7	3
400	Anti-Inflammatory Nutrients and Obesity-Associated Metabolic-Inflammation: State of the Art and Future Direction.. <i>Nutrients</i> , <b>2022</b> , 14,	6.7	8
399	Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience.. <i>Frontiers in Neurology</i> , <b>2022</b> , 13, 783737	4.1	
398	A practical nutritional guideline to manage neuroendocrine neoplasms through chronotype and sleep.. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2022</b> , 1-18	11.5	0
397	An unusual case report of polycystic ovary syndrome.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1	5.2	
396	Gestational obesity: An unconventional endocrine disruptor for the fetus.. <i>Biochemical Pharmacology</i> , <b>2022</b> , 198, 114974	6	0
395	Could very low-calorie ketogenic diets turn off low grade inflammation in obesity? Emerging evidence.. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2022</b> , 1-17	11.5	1
394	The role of outdoor and indoor air quality in the spread of SARS-CoV-2: Overview and recommendations by the research group on COVID-19 and particulate matter (RESCOP commission).. <i>Environmental Research</i> , <b>2022</b> , 113038	7.9	2

393	Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.C.A. registry.. <i>Internal and Emergency Medicine</i> , <b>2022</b> , 1	3.7	0
392	Mediterranean Diet: What Are the Consequences for Menopause?. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 886824	5.7	0
391	From Gut Microbiota through Low-Grade Inflammation to Obesity: Key Players and Potential Targets. <i>Nutrients</i> , <b>2022</b> , 14, 2103	6.7	3
390	Pancreatic Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 696-704	5.6	4
389	Treatment of Paget's disease of the bone: long-term effect of neridronate in a real-life setting.. <i>Minerva Endocrinology</i> , <b>2021</b> , 46, 374-383	2.5	
388	"Forever young at the table": metabolic effects of eating speed in obesity.. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 530	8.5	1
387	Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. <i>Translational Oncology</i> , <b>2021</b> , 15, 101269	4.9	0
386	Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 769744	5.7	1
385	The clock diet: a practical nutritional guide to manage obesity through chrononutrition. <i>Minerva Medica</i> , <b>2021</b> ,	2.2	2
384	Diet as a possible influencing factor in thyroid cancer incidence: the point of view of the nutritionist. <i>Panminerva Medica</i> , <b>2021</b> , 63, 349-360	2	1
383	Is there a relationship between the ketogenic diet and sleep disorders?. <i>International Journal of Food Sciences and Nutrition</i> , <b>2021</b> , 1-11	3.7	3
382	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 563-579	10.5	6
381	Nutrition and immune system: from the Mediterranean diet to dietary supplementary through the microbiota. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 61, 3066-3090	11.5	30
380	Improving sleep disturbances in obesity by nutritional strategies: review of current evidence and practical guide. <i>International Journal of Food Sciences and Nutrition</i> , <b>2021</b> , 72, 579-591	3.7	6
379	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 1066-1085	5.6	31
378	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 511-525	10.5	2
377	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 649496	5.7	7
376	The impact of obesity on immune response to infection: Plausible mechanisms and outcomes. <i>Obesity Reviews</i> , <b>2021</b> , 22, e13216	10.6	10

375	Phase Angle as an Easy Diagnostic Tool of Meta-Inflammation for the Nutritionist. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	7
374	Phase angle and Mediterranean diet in patients with acne: Two easy tools for assessing the clinical severity of disease. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 171	8.5	3
373	Nutritional guidelines for the management of insulin resistance. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 1-14	11.5	7
372	Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 665631	5.7	3
371	An Italian Survey on Dietary Habits and Changes during the COVID-19 Lockdown. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	13
370	Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 667784	5.7	4
369	Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel. <i>Endocrine</i> , <b>2021</b> , 72, 597-603	4	14
368	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 44, 2845-2847	5.2	6
367	Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 665698	5.7	0
366	Association of the Chronotype Score with Circulating Trimethylamine N-Oxide (TMAO) Concentrations. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	1
365	Vitamin D in obesity and obesity-related diseases: an overview. <i>Minerva Endocrinology</i> , <b>2021</b> , 46, 177-192.	12.5	16
364	Association of Trimethylamine N-Oxide (TMAO) with the Clinical Severity of Hidradenitis Suppurativa (Acne Inversa). <i>Nutrients</i> , <b>2021</b> , 13,	6.7	2
363	Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 700806	5.7	0
362	Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 651438	5.7	0
361	Mediterranean diet as medical prescription in menopausal women with obesity: a practical guide for nutritionists. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 61, 1201-1211	11.5	10
360	The opera prevention project. <i>International Journal of Food Sciences and Nutrition</i> , <b>2021</b> , 72, 1-3	3.7	14
359	Nutritional status and follicular-derived thyroid cancer: An update. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 61, 25-59	11.5	25
358	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 367-374	3.3	3

357	A practical nutritional guide for the management of sleep disturbances in menopause. <i>International Journal of Food Sciences and Nutrition</i> , <b>2021</b> , 72, 432-446	3.7	3
356	Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e316-e327	5.6	3
355	Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 44, 957-968	5.2	2
354	Characterization with hybrid imaging of cystic pheochromocytomas: correlation with pathology. <i>Quantitative Imaging in Medicine and Surgery</i> , <b>2021</b> , 11, 862-869	3.6	2
353	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	6
352	Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 324	8.5	3
351	Coffee consumption, health benefits and side effects: a narrative review and update for dietitians and nutritionists. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 1-24	11.5	0
350	Hyperprolactinemia after menopause: Diagnosis and management. <i>Maturitas</i> , <b>2021</b> , 151, 36-40	5	0
349	Nutritional management of type 2 diabetes in subjects with obesity: an international guideline for clinical practice. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2021</b> , 1-13	11.5	1
348	Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. <i>Endocrine</i> , <b>2021</b> , 1	4	2
347	Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 475-484	6.5	0
346	PCOS and nutritional approaches: Differences between lean and obese phenotype. <i>Metabolism Open</i> , <b>2021</b> , 12, 100123	2.8	6
345	European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis. <i>Obesity Facts</i> , <b>2021</b> , 14, 222-245	5.1	21
344	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. <i>Obesity Reviews</i> , <b>2021</b> , e13390	10.6	3
343	Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
342	Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature. <i>Journal of Endocrinological Investigation</i> , <b>2020</b> , 43, 1429-1445	5.2	7
341	Influence of the Mediterranean Diet on 25-Hydroxyvitamin D Levels in Adults. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	17
340	Diagnosis of Flier's syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature. <i>Endocrine</i> , <b>2020</b> , 69, 73-78	4	1

339	Chronotype and Adherence to the Mediterranean Diet in Obesity: Results from the Opera Prevention Project. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	26
338	Sleep Quality in Obesity: Does Adherence to the Mediterranean Diet Matter?. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	29
337	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , <b>2020</b> , 69, 441-450	10	10
336	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 654-656	18.1	13
335	COVID-19: Time for Post-Exposure Prophylaxis?. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	6
334	Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2020</b> , 21, 599-612	10.5	14
333	Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak. <i>BMJ, The</i> , <b>2020</b> , 368, m1254	5.9	60
332	Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?. <i>Trends in Endocrinology and Metabolism</i> , <b>2020</b> , 31, 631-641	8.8	6
331	Rethinking the role of the school after COVID-19. <i>Lancet Public Health, The</i> , <b>2020</b> , 5, e370	22.4	49
330	Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1047	5.3	5
329	Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
328	Sleep Apnea, Obesity, and Disturbed Glucose Homeostasis: Epidemiologic Evidence, Biologic Insights, and Therapeutic Strategies. <i>Current Obesity Reports</i> , <b>2020</b> , 9, 30-38	8.4	37
327	Searching for SARS-COV-2 on Particulate Matter: A Possible Early Indicator of COVID-19 Epidemic Recurrence. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	71
326	Commentary: Obesity: The "Achilles heel" for COVID-19?. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 108, 154251	12.7	120
325	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	5
324	The Sun's Vitamin in Adult Patients Affected by Prader-Willi Syndrome. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	4
323	Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia. <i>Endocrine Connections</i> , <b>2020</b> , 9, 144-153	3.5	11
322	Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , <b>2020</b> , 182, 439-446	6.5	11

321	Vitamin D and Sleep Regulation: Is there a Role for Vitamin D?. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 2492-2496	3.3	14
320	Bone metabolism, bone mass and structural integrity profile in professional male football players. <i>Journal of Sports Medicine and Physical Fitness</i> , <b>2020</b> , 60, 912-918	1.4	2
319	Specific cut-off for the 25-OH vitamin D levels to predict the highest Body Mass Index and fat mass: a sex-related analysis in obese patients. <i>Minerva Endocrinologica</i> , <b>2020</b> , 45, 266-268	1.9	8
318	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. <i>Minerva Endocrinologica</i> , <b>2020</b> , 45, 127-137	1.9	12
317	Mediterranean diet and breast cancer risk: a narrative review. <i>Minerva Endocrinology</i> , <b>2020</b> ,	2.5	5
316	Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 604341	5.7	10
315	Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 10,	5.1	10
314	Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 146, 102840	7	4
313	Vitamin D testing: advantages and limits of the current assays. <i>European Journal of Clinical Nutrition</i> , <b>2020</b> , 74, 231-247	5.2	37
312	Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. <i>Cancer Cytopathology</i> , <b>2020</b> , 128, 107-118	3.9	26
311	Mediterranean diet as tool to manage obesity in menopause: A narrative review. <i>Nutrition</i> , <b>2020</b> , 79-80, 110991	4.8	15
310	Ketogenic diet: a tool for the management of neuroendocrine neoplasms?. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2020</b> , 1-11	11.5	4
309	From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. <i>International Journal of Obesity Supplements</i> , <b>2020</b> , 10, 35-49	13.3	15
308	Nutrigenetics-personalized nutrition in obesity and cardiovascular diseases. <i>International Journal of Obesity Supplements</i> , <b>2020</b> , 10, 1-13	13.3	16
307	Could ketogenic diet "starve" cancer? Emerging evidence. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2020</b> , 1-22	11.5	14
306	Sleep disturbances: one of the culprits of obesity-related cardiovascular risk?. <i>International Journal of Obesity Supplements</i> , <b>2020</b> , 10, 62-72	13.3	2
305	Phase Angle: Could Be an Easy Tool to Detect Low-Grade Systemic Inflammation in Adults Affected by Prader-Willi Syndrome?. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	5
304	Maternal obesity: focus on offspring cardiometabolic outcomes. <i>International Journal of Obesity Supplements</i> , <b>2020</b> , 10, 27-34	13.3	4

303	Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2020</b> , 1-17	11.5	14
302	Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index. <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 318	8.5	56
301	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. <i>Annals of Surgery</i> , <b>2020</b> , 271, 527-533	7.8	27
300	Breast cancer prevention in premenopausal women: role of the Mediterranean diet and its components. <i>Nutrition Research Reviews</i> , <b>2020</b> , 33, 19-32	7	20
299	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors Journal of Clinical Endocrinology and Metabolism, <b>2020</b> , 105,	5.6	16
298	Nutritional recommendations for CoVID-19 quarantine. <i>European Journal of Clinical Nutrition</i> , <b>2020</b> , 74, 850-851	5.2	212
297	Papillary thyroid carcinoma arising in ectopic thyroid tissue within sternocleidomastoid muscle: a review of current literature. <i>Minerva Endocrinologica</i> , <b>2020</b> , 45, 318-325	1.9	3
296	Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy. <i>ClinicoEconomics and Outcomes Research</i> , <b>2019</b> , 11, 525-537	1.7	4
295	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. <i>Cancers</i> , <b>2019</b> , 11,	6.6	16
294	Somatotropic Axis and Obesity: Is There Any Role for the Mediterranean Diet?. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	16
293	Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). <i>Nutrients</i> , <b>2019</b> , 11,	6.7	77
292	Italian university rectors for health and environment: the U4ALL initiative. <i>Lancet, The</i> , <b>2019</b> , 394, 1319	40	1
291	Irritable bowel syndrome: a new therapeutic target when treating obesity?. <i>Hormones</i> , <b>2019</b> , 18, 395-399,	3.1	9
290	Comment on 'Acne and nutrition: hypotheses, myths and facts'. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, e418-e419	4.6	3
289	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1456-1460	3.3	18
288	A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). <i>Nutrients</i> , <b>2019</b> , 11,	6.7	39
287	Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). <i>Journal of Endocrinological Investigation</i> , <b>2019</b> , 42, 1365-1386	5.2	84
286	Prader- Willi syndrome: An uptodate on endocrine and metabolic complications. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2019</b> , 20, 239-250	10.5	33



285	How much does obesity affect the male reproductive function?. <i>International Journal of Obesity Supplements</i> , <b>2019</b> , 9, 50-64	13.3	18
284	From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?. <i>Hormones</i> , <b>2019</b> , 18, 245-250	3.1	29
283	A rare rarity: Neuroendocrine tumor of the esophagus. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 137, 92-107	7	20
282	The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease. <i>Neurological Sciences</i> , <b>2019</b> , 40, 1351-1356	3.5	7
281	Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , <b>2019</b> , 66, 417-424	4	11
280	Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. <i>International Journal of Obesity Supplements</i> , <b>2019</b> , 9, 32-49	13.3	14
279	Gut microbiota: a new path to treat obesity. <i>International Journal of Obesity Supplements</i> , <b>2019</b> , 9, 10-19	13.3	114
278	Taste and the Gastrointestinal tract: from physiology to potential therapeutic target for obesity. <i>International Journal of Obesity Supplements</i> , <b>2019</b> , 9, 1-9	13.3	6
277	Phase Angle: A Possible Biomarker to Quantify Inflammation in Subjects with Obesity and 25(OH)D Deficiency. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	25
276	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. <i>World Neurosurgery</i> , <b>2019</b> , 127, 695-709	2.1	9
275	The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 356	8.5	40
274	SAT-259 Natural History of Anthropometric Parametres of Obesity in Children Affected by X-Linked Hypophosphatemia: Longitudinal Obserbational Study. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3,	0.4	1
273	Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 610-617	3.3	15
272	The role of insulin-like growth factor system in the adrenocortical tumors. <i>Minerva Endocrinologica</i> , <b>2019</b> , 44, 43-57	1.9	12
271	Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. <i>Endokrynologia Polska</i> , <b>2019</b> , 70, 305-312	1.1	5
270	Health-care inequalities in Italy: challenges for the Government. <i>Lancet Public Health, The</i> , <b>2019</b> , 4, e605	22.4	6
269	Sex Differences of Vitamin D Status across BMI Classes: An Observational Prospective Cohort Study. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	45
268	Trimethylamine N-oxide, Mediterranean diet, and nutrition in healthy, normal-weight adults: also a matter of sex?. <i>Nutrition</i> , <b>2019</b> , 62, 7-17	4.8	70

267	Gender-related issues in the pharmacology of new anti-obesity drugs. <i>Obesity Reviews</i> , <b>2019</b> , 20, 375-384	10.6	14
266	The lullaby of the sun: the role of vitamin D in sleep disturbance. <i>Sleep Medicine</i> , <b>2019</b> , 54, 262-265	4.6	47
265	Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules. <i>Chemosphere</i> , <b>2019</b> , 218, 885-894	8.4	42
264	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 429-443	4.9	8
263	Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: a pilot study. <i>Hormones</i> , <b>2019</b> , 18, 75-84	3.1	23
262	Obesity and sleep disturbance: the chicken or the egg?. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2019</b> , 59, 2158-2165	11.5	53
261	The management of neuroendocrine tumours: A nutritional viewpoint. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2019</b> , 59, 1046-1057	11.5	26
260	Could hop-derived bitter compounds improve glucose homeostasis by stimulating the secretion of GLP-1?. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2019</b> , 59, 528-535	11.5	8
259	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , <b>2018</b> , 103, 151-163	3.9	14
258	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , <b>2018</b> , 62, 215-233	4	14
257	The effects of hyperprolactinemia and its control on metabolic diseases. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2018</b> , 13, 99-106	4.1	12
256	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , <b>2018</b> , 61, 118-124	4	13
255	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , <b>2018</b> , 155, 479-489.e7	13.3	36
254	Coffee consumption, metabolic syndrome and clinical severity of psoriasis: good or bad stuff?. <i>Archives of Toxicology</i> , <b>2018</b> , 92, 1831-1845	5.8	32
253	Obesity and breast cancer in premenopausal women: Current evidence and future perspectives. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2018</b> , 230, 217-221	2.4	35
252	The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. <i>Endocrine</i> , <b>2018</b> , 62, 46-56	4	9
251	Gut: A key player in the pathogenesis of type 2 diabetes?. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2018</b> , 58, 1294-1309	11.5	20
250	The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?. <i>Endocrine</i> , <b>2018</b> , 60, 15-27	4	10

249	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 78, 141-154	12.7	28
248	Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study. <i>Neuroendocrinology</i> , <b>2018</b> , 106, 264-273	5.6	6
247	Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. <i>Nutrition Research Reviews</i> , <b>2018</b> , 31, 291-301	7	50
246	Heavy Environmental Pressure in Campania and Other Italian Regions: A Short Review of Available Evidence. <i>International Journal of Environmental Research and Public Health</i> , <b>2018</b> , 15,	4.6	10
245	Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 67, 1-9	14.4	21
244	Nutritional and Environmental Factors in Thyroid Carcinogenesis. <i>International Journal of Environmental Research and Public Health</i> , <b>2018</b> , 15,	4.6	33
243	Role of Nutrition and Adherence to the Mediterranean Diet in the Multidisciplinary Approach of Hidradenitis Suppurativa: Evaluation of Nutritional Status and Its Association with Severity of Disease. <i>Nutrients</i> , <b>2018</b> , 11,	6.7	43
242	Nutrition, inflammation and liver-spleen axis. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2018</b> , 58, 3141-3158	11.5	38
241	Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	98
240	Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	43
239	Nutrition and neuroendocrine tumors: An update of the literature. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2018</b> , 19, 159-167	10.5	23
238	Influence of nutrition on somatotrophic axis: Milk consumption in adult individuals with moderate-severe obesity. <i>Clinical Nutrition</i> , <b>2017</b> , 36, 293-301	5.9	31
237	Vitamin D and pancreas: The role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2017</b> , 57, 3472-3488	11.5	47
236	Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. <i>Neurosurgical Review</i> , <b>2017</b> , 40, 105-114	3.9	46
235	Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2017</b> , 18, 273-283	10.5	53
234	Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2017</b> , 18, 335-346	10.5	91
233	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , <b>2017</b> , 58, 349-359	4	48
232	Long-term safety and efficacy of Omnitrope in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 669-678	5.2	4

231	Low vitamin D status and obesity: Role of nutritionist. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2017</b> , 18, 215-225	10.5	79
230	Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2017</b> , 18, 195-205	10.5	105
229	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 577-589	5.2	39
228	Selenium supplementation modulates apoptotic processes in thyroid follicular cells. <i>BioFactors</i> , <b>2017</b> , 43, 415-423	6.1	16
227	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, 453-461	6.5	39
226	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 1209-1224	4.9	8
225	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , <b>2017</b> , 158, 1527-1532	4.8	10
224	Vitamin D and cardiovascular disease: From atherosclerosis to myocardial infarction and stroke. <i>International Journal of Cardiology</i> , <b>2017</b> , 230, 577-584	3.2	71
223	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , <b>2017</b> , 57, 539-543	4	6
222	Obesogenic endocrine disruptors and obesity: myths and truths. <i>Archives of Toxicology</i> , <b>2017</b> , 91, 3469-3475	3.85	39
221	Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study. <i>Endocrine Pathology</i> , <b>2017</b> , 28, 187-197	4.2	2
220	Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Patients: A Novel Association. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2017</b> , 2017, 6101254	6.7	31
219	Mediterranean Diet and Phase Angle in a Sample of Adult Population: Results of a Pilot Study. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	42
218	Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 661-671	5.6	16
217	The safety of available treatments options for neuroendocrine tumors. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 1149-1161	4.1	17
216	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, 495-504	5.7	41
215	Preliminary results demonstrating the impact of Mediterranean diet on bone health. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 81	8.5	41
214	Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 1373-1380	5.2	8

213	Animal models of medullary thyroid cancer: state of the art and view to the future. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, R1-R12	5.7	22
212	Vitamin D and chronic diseases: the current state of the art. <i>Archives of Toxicology</i> , <b>2017</b> , 91, 97-107	5.8	78
211	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , <b>2017</b> , 56, 633-638	4	25
210	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 9-20	5.2	29
209	Low serum vitamin D-status, air pollution and obesity: A dangerous liaison. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2017</b> , 18, 207-214	10.5	43
208	Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health. <i>International Journal of Environmental Research and Public Health</i> , <b>2017</b> , 14,	4.6	1
207	Multifocality and Hashimoto's thyroiditis as independent predictors of structural recurrence in a cohort of low risk intrathyroidal papillary thyroid cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e17577-e17577 <sup>2</sup>		
206	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186508	3.7	21
205	Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). <i>Endocrine</i> , <b>2016</b> , 52, 495-506	4	32
204	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , <b>2016</b> , 51, 131-9	4	31
203	Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial. <i>Clinical Endocrinology</i> , <b>2016</b> , 85, 764-771	3.4	39
202	Cardiovascular risk in adult hypopituitary patients with growth hormone deficiency: is there a role for vitamin D?. <i>Endocrine</i> , <b>2016</b> , 52, 111-9	4	39
201	Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. <i>Journal of Investigative Medicine</i> , <b>2016</b> , 64, 1025-34	2.9	13
200	Adrenocortical tumors and insulin resistance: What is the first step?. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2785-94	7.5	17
199	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. <i>Bone</i> , <b>2016</b> , 86, 79-85	4.7	17
198	Long period fiber grating nano-optrode for cancer biomarker detection. <i>Biosensors and Bioelectronics</i> , <b>2016</b> , 80, 590-600	11.8	60
197	Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. <i>Annals of Nuclear Medicine</i> , <b>2016</b> , 30, 234-41	2.5	7
196	Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome. <i>Endocrine</i> , <b>2016</b> , 53, 538-42	4	24

195	Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). <i>Endocrine</i> , <b>2016</b> , 52, 488-94	4	30
194	Letter to the Editor: Vitamin D: A Wonder Drug for the Cure of Type 2 Diabetes?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, L43-4	5.6	2
193	Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. <i>Oncotarget</i> , <b>2016</b> , 7, 5538-47	3.3	24
192	NutriLive: An Integrated Nutritional Approach as a Sustainable Tool to Prevent Malnutrition in Older People and Promote Active and Healthy Ageing. The EIP-AHA Nutrition Action Group. <i>Advances in Public Health</i> , <b>2016</b> , 2016, 1-9	2.5	8
191	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. <i>Oncotarget</i> , <b>2016</b> , 7, 18865-75	3.3	22
190	Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. <i>Oncologist</i> , <b>2016</b> , 21, 875-86	5.7	9
189	Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 130	8.5	39
188	Osteoporosis across chronic liver disease. <i>Osteoporosis International</i> , <b>2016</b> , 27, 1967-77	5.3	20
187	Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. <i>Clinical and Experimental Dermatology</i> , <b>2016</b> , 41, 38-42	1.8	47
186	Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. <i>Neuroendocrinology</i> , <b>2015</b> , 101, 66-81	5.6	19
185	Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. <i>Endocrine</i> , <b>2015</b> , 50, 824-5	4	2
184	Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 18	8.5	83
183	Insulin-Mediated Diseases: Adrenal Mass and Polycystic Ovary Syndrome. <i>Trends in Endocrinology and Metabolism</i> , <b>2015</b> , 26, 512-514	8.8	13
182	Comment on Krul-Poel et al. Effect of Vitamin D Supplementation on Glycemic Control in Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. <i>Diabetes Care</i> 2015;38:1420-1426. <i>Diabetes Care</i> , <b>2015</b> , 38, e190	14.6	1
181	Vitamin D and thyroid disease: to D or not to D?. <i>European Journal of Clinical Nutrition</i> , <b>2015</b> , 69, 291-6	5.2	50
180	Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery. <i>Journal of Endocrinological Investigation</i> , <b>2015</b> , 38, 373-4	5.2	2
179	The evolving field of kinase inhibitors in thyroid cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 60-73	7	26
178	Prognostic role of the CDKN1B V109G polymorphism in multiple endocrine neoplasia type 1. <i>Journal of Cellular and Molecular Medicine</i> , <b>2015</b> , 19, 1735-41	5.6	19

177	Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1033-4	6.1	1
176	Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 303	8.5	46
175	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. <i>Orphanet Journal of Rare Diseases</i> , <b>2015</b> , 10, 91	4.2	15
174	Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population. <i>Journal of Aging Research</i> , <b>2015</b> , 2015, 682503	2.3	31
173	A Community-Based, Technology-Supported Health Service for Detecting and Preventing Frailty among Older Adults: A Participatory Design Development Process. <i>Journal of Aging Research</i> , <b>2015</b> , 2015, 216084	2.3	34
172	The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. <i>Endocrine</i> , <b>2015</b> , 50, 568-74	4	18
171	Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. <i>Journal of Endocrinological Investigation</i> , <b>2015</b> , 38, 1099-109	5.2	12
170	Pituitary function and morphology in Fabry disease. <i>Endocrine</i> , <b>2015</b> , 50, 483-8	4	4
169	Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status. <i>Growth Hormone and IGF Research</i> , <b>2015</b> , 25, 28-33	2	25
168	Treatment of pituitary tumours in 2014: Advances in therapy of adenomas secreting GH, ACTH and TSH. <i>Nature Reviews Endocrinology</i> , <b>2015</b> , 11, 73-4	15.2	5
167	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. <i>Gene</i> , <b>2014</b> , 534, 282-5	3.8	22
166	Lipid profile in nonobese pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. <i>Steroids</i> , <b>2014</b> , 88, 36-43	2.8	48
165	Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 791-9	5.6	254
164	Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells. <i>Scientific World Journal, The</i> , <b>2014</b> , 2014, 282147	2.2	38
163	Intracellular inactivation of thyroid hormone is a survival mechanism for muscle stem cell proliferation and lineage progression. <i>Cell Metabolism</i> , <b>2014</b> , 20, 1038-48	24.6	75
162	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, 601-13	5.7	22
161	Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 263-73	6.5	27
160	Diabetes and Obesity as Independent Risk Factors for Osteoporosis in Postmenopausal Women: A Population Study. <i>European Journal of Inflammation</i> , <b>2014</b> , 12, 479-487	0.3	

159	Cushing, acromegaly, GH deficiency and tendons. <i>Muscles, Ligaments and Tendons Journal</i> , <b>2014</b> , 4, 329-329		8
158	Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2014</b> , 28, 733-41	0.7	2
157	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Orphan Drugs</i> , <b>2013</b> , 1, 557-567	1.1	2
156	Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 325-330	7.9	45
155	Low 25-hydroxyvitamin D levels and low bone density assessed by quantitative ultrasonometry in a cohort of postmenopausal Italian nuns. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 308-312	3.5	4
154	Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. <i>Clinical Endocrinology</i> , <b>2013</b> , 78, 447-53	3.4	65
153	Fibrous Variant of Hashimoto's Thyroiditis as a Diagnostic Pitfall in Thyroid Pathology. <i>Case Reports in Endocrinology</i> , <b>2013</b> , 2013, 308908	1.2	9
152	Effect of cabergoline on metabolism in prolactinomas. <i>Neuroendocrinology</i> , <b>2013</b> , 98, 299-310	5.6	42
151	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 211-6	3.4	7
150	Polycystic Ovary Syndrome and Hepatic Steatosis: Could Low-Grade Chronic Inflammation Be Mediated by the Spleen?. <i>European Journal of Inflammation</i> , <b>2013</b> , 11, 179-191	0.3	3
149	Hashimoto's Thyroiditis and Entero-Chromaffin-like Cell Hyperplasia: Early Detection and Somatostatin Analogue Treatment. <i>European Journal of Inflammation</i> , <b>2013</b> , 11, 863-870	0.3	3
148	Quality of life in patients with Cushing's disease: a modern approach. <i>Clinical Endocrinology</i> , <b>2012</b> , 76, 776-7	3.4	10
147	Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. <i>Pituitary</i> , <b>2012</b> , 15, 50-8	4.3	37
146	A 12-month phase 3 study of pasireotide in Cushing's disease. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 914-24	59.2	448
145	L02 Insulin sensitivity and early-phase insulin secretion in normoglycemic patients with huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, A43.4-A44	5.5	
144	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 817-23	5.2	48
143	Medical treatment of prolactinomas. <i>Nature Reviews Endocrinology</i> , <b>2011</b> , 7, 267-78	15.2	112
142	Frontiers in cancer endocrinology. <i>Frontiers in Endocrinology</i> , <b>2011</b> , 2, 7	5.7	



141	Diabetes and cancer. <i>Frontiers in Endocrinology</i> , <b>2011</b> , 2, 22	5.7	1
140	Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. <i>Clinical Endocrinology</i> , <b>2011</b> , 74, 234-40	3.4	6
139	Aortic root ectasia in patients with acromegaly: an emerging complication. <i>Clinical Endocrinology</i> , <b>2011</b> , 75, 420-1	3.4	7
138	Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. <i>Journal of Translational Medicine</i> , <b>2011</b> , 9, 136	8.5	41
137	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. <i>European Journal of Endocrinology</i> , <b>2011</b> , 165, 713-21	6.5	57
136	Resistance to somatostatin analogs in acromegaly. <i>Endocrine Reviews</i> , <b>2011</b> , 32, 247-71	27.2	186
135	Therapy of aggressive pituitary tumors. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1561-70	4	49
134	Spleen: A new role for an old player?. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 3776-84	5.6	85
133	Dose optimization of somatostatin analogues for acromegaly patients. <i>Journal of Endocrinological Investigation</i> , <b>2010</b> , 33, 125-7	5.2	4
132	Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. <i>Progress in Brain Research</i> , <b>2010</b> , 182, 281-94	2.9	24
131	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. <i>BMC Endocrine Disorders</i> , <b>2010</b> , 10, 10	3.3	39
130	A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 4414-22	5.6	55
129	Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2907-14	5.6	41
128	Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 528-37	5.6	47
127	Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 3746-56	5.6	107
126	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. <i>Acta Diabetologica</i> , <b>2009</b> , 46, 85-95	3.9	95
125	Medical therapy of pituitary adenomas: effects on tumor shrinkage. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2009</b> , 10, 111-23	10.5	43
124	Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. <i>Clinical Endocrinology</i> , <b>2009</b> , 70, 757-68	3.4	90

123	Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , <b>2009</b> , 71, 237-45	3.4	51
122	Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy. <i>Andrologia</i> , <b>2009</b> , 32, 147-154	2.4	
121	Pituitary tumours: the prolactinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 23, 575-96	6.5	107
120	5 Long-term acromegaly and associated cardiovascular complications: a case-based review. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 23 Suppl 1, S31-8	6.5	12
119	The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 223-30	5.6	250
118	Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. <i>Clinical Endocrinology</i> , <b>2008</b> , 68, 66-71	3.4	98
117	GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. <i>Clinical Endocrinology</i> , <b>2008</b> , 69, 613-20	3.4	33
116	The GH-IGF-I axis and the cardiovascular system: clinical implications. <i>Clinical Endocrinology</i> , <b>2008</b> , 69, 347-58	3.4	154
115	Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. <i>Human Reproduction</i> , <b>2008</b> , 23, 642-50	5.7	157
114	Body fat in men with prolactinoma. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 985-90	5.2	15
113	Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. <i>European Journal of Endocrinology</i> , <b>2008</b> , 159, 389-97	6.5	80
112	Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 3777-84	5.6	127
111	No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 2243-8	5.6	23
110	Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 2639-46	5.6	64
109	Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 3416-24	5.6	50
108	Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 3436-42	5.6	26
107	Medical therapy for clinically non-functioning pituitary adenomas. <i>Endocrine-Related Cancer</i> , <b>2008</b> , 15, 905-15	5.7	131
106	Medical consequences of acromegaly: what are the effects of biochemical control?. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2008</b> , 9, 21-31	10.5	28

105	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , <b>2008</b> , 23, 1331-1331		
104	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. <i>Journal of Endocrinological Investigation</i> , <b>2007</b> , 30, 497-506	5.2	13
103	Pegvisomant in acromegaly: why, when, how. <i>Journal of Endocrinological Investigation</i> , <b>2007</b> , 30, 693-9	5.2	31
102	Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. <i>Clinical Endocrinology</i> , <b>2007</b> , 66, 714-22	3.4	22
101	Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. <i>Clinical Endocrinology</i> , <b>2007</b> , 67, 426-33	3.4	77
100	Body fat in nonobese women with prolactinoma treated with dopamine agonists. <i>Clinical Endocrinology</i> , <b>2007</b> , 67, 845-52	3.4	33
99	The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3854-60	5.6	47
98	Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. <i>European Journal of Endocrinology</i> , <b>2007</b> , 157, 579-87	6.5	65
97	Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 1379-84	5.6	136
96	The importance of presurgical somatostatin analogue therapy in acromegaly. <i>Endokrynologia Polska</i> , <b>2007</b> , 58, 356-60	1.1	4
95	Cardiopulmonary impairment in young women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 2967-71	5.6	55
94	The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 2191-200	5.6	34
93	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. <i>European Journal of Endocrinology</i> , <b>2006</b> , 154, 467-77	6.5	133
92	Advances in the treatment of prolactinomas. <i>Endocrine Reviews</i> , <b>2006</b> , 27, 485-534	27.2	564
91	Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 2112-8	5.6	104
90	Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2006</b> , 2, 200-10		46
89	Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 85-92	5.6	146
88	First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. <i>Journal of Endocrinological Investigation</i> , <b>2006</b> , 29, 1017-20	5.2	40

87	Cardiovascular risk in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , <b>2006</b> , 86 Suppl 1, S20-1	4.8	48
86	Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. <i>Growth Hormone and IGF Research</i> , <b>2006</b> , 16 Suppl A, S41-8	2	69
85	The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. <i>Clinical Endocrinology</i> , <b>2006</b> , 64, 307-13	3.4	39
84	First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. <i>Clinical Endocrinology</i> , <b>2006</b> , 64, 342-51	3.4	63
83	Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. <i>Clinical Endocrinology</i> , <b>2006</b> , 65, 250-6	3.4	38
82	Growth hormone/insulin-like growth factor-I system and connective tissues: basic aspects and clinical implications. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 29-42, viii	2.4	6
81	Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. <i>Journal of Endocrinological Investigation</i> , <b>2005</b> , 28, 440-8	5.2	53
80	The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 2-5	5.6	169
79	Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. <i>Clinical Endocrinology</i> , <b>2005</b> , 63, 342-9	3.4	24
78	Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 6072-6	5.6	116
77	Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 2659-65	5.6	32
76	Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 2056-62	5.6	48
75	Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 5146-55	5.6	40
74	Severe systemic complications of acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>2005</b> , 28, 65-77	5.2	12
73	The acromegalic arthropathy. <i>Journal of Endocrinological Investigation</i> , <b>2005</b> , 28, 24-31	5.2	19
72	New perspectives in the medical treatment of acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>2005</b> , 28, 58-66	5.2	2
71	The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 5998-6004	5.6	91
70	Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 2770-5	5.6	19

69	Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 4588-93	5.6	273
68	The heart: an end-organ of GH action. <i>European Journal of Endocrinology</i> , <b>2004</b> , 151 Suppl 1, S93-101	6.5	66
67	Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. <i>Clinical Endocrinology</i> , <b>2004</b> , 61, 360-6 <sup>3.4</sup>	3.4	43
66	Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 1704-11	5.6	156
65	Systemic complications of acromegaly: epidemiology, pathogenesis, and management. <i>Endocrine Reviews</i> , <b>2004</b> , 25, 102-52	27.2	880
64	Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. <i>Reproductive BioMedicine Online</i> , <b>2004</b> , 9, 505-10	4	55
63	The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3696-701	5.6	217
62	Cardiovascular effects of growth hormone treatment: potential risks and benefits. <i>Hormone Research in Paediatrics</i> , <b>2004</b> , 62 Suppl 3, 42-50	3.3	7
61	Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 88-94	5.6	22
60	Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. <i>Endocrine</i> , <b>2003</b> , 20, 279-83		25
59	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , <b>2003</b> , 58, 169-76	3.4	87
58	Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 2023-33	59.2	255
57	High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3196-201	5.6	98
56	Influence of growth hormone on cardiovascular health and disease. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , <b>2003</b> , 2, 347-56		4
55	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. <i>European Journal of Endocrinology</i> , <b>2003</b> , 148, 325-31	6.5	158
54	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. <i>European Journal of Endocrinology</i> , <b>2003</b> , 148, 31-8	6.5	42
53	The treatment algorithm of acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>2003</b> , 26, 39-45	5.2	5
52	The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. <i>Journal of Endocrinological Investigation</i> , <b>2003</b> , 26, 53-6	5.2	4

51	(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. <i>Clinical Endocrinology</i> , <b>2002</b> , 56, 713-21	3.4	6
50	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 303-9	6.5	57
49	The cardiovascular risk of GH-deficient adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 3650-5	5.6	96
48	Dopamine receptor agonists for treating prolactinomas. <i>Expert Opinion on Investigational Drugs</i> , <b>2002</b> , 11, 787-800	5.9	90
47	The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 1088-93	5.6	86
46	Cardiovascular consequences of early-onset growth hormone excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 3097-104	5.6	74
45	Lymphocyte subset pattern in acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 125-8	5.2	19
44	Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 142-51	5.2	19
43	Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 163-8	5.2	11
42	Gender- and age-related differences in the endocrine parameters of acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 532-8	5.2	45
41	Is the impact of GH deficiency on the heart dependent on time of onset?. <i>International Journal of Clinical Practice, Supplement</i> , <b>2002</b> , 27-31		
40	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 97-106	3.4	6
39	Growth hormone and the heart. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 137-54	3.4	276
38	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 515-24	3.4	84
37	Are patients with acromegaly at high risk for dysrhythmias?. <i>Clinical Endocrinology</i> , <b>2001</b> , 55, 305-6	3.4	20
36	Cardiovascular complications in acromegaly: methods of assessment. <i>Pituitary</i> , <b>2001</b> , 4, 251-7	4.3	22
35	Spine abnormalities and damage in patients cured from Cushing's disease. <i>Pituitary</i> , <b>2001</b> , 4, 153-61	4.3	28
34	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. <i>Pituitary</i> , <b>2001</b> , 4, 187-93	4.3	1

33	Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. <i>European Journal of Endocrinology</i> , <b>2001</b> , 144, 499-507	6.5	92
32	Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 3001-8	5.6	80
31	In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. <i>Journal of Endocrinological Investigation</i> , <b>2001</b> , 24, 522-8	5.2	19
30	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. <i>European Journal of Endocrinology</i> , <b>2000</b> , 143 Suppl 1, S35-42	6.5	5
29	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clinical Endocrinology</i> , <b>2000</b> , 52, 319-27	3.4	76
28	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with <sup>123</sup> I-methoxybenzamide. <i>Clinical Endocrinology</i> , <b>2000</b> , 52, 437-45	3.4	40
27	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. <i>Clinical Endocrinology</i> , <b>2000</b> , 53, 53-60	3.4	60
26	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , <b>2000</b> , 53, 13-9	3.4	43
25	Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 193-9	5.6	137
24	Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 3720-5	5.6	56
23	Muscle sympathetic nerve activity in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 3203-7	5.6	14
22	Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. <i>European Journal of Endocrinology</i> , <b>2000</b> , 143, 61-9	6.5	10
21	Cabergoline. <i>Expert Opinion on Pharmacotherapy</i> , <b>2000</b> , 1, 555-74	4	55
20	Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1919-24	5.6	138
19	Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 2664-72	5.6	291
18	The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1277-82	5.6	80
17	Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1986-91	5.6	58
16	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , <b>1999</b> , 1, 115-20	4.3	69

15	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , <b>1998</b> , 49, 77-84	3.4	12
14	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Urology</i> , <b>1998</b> , 160, 1583-1584	2.5	
13	Treatment of prolactinomas. <i>Annals of Medicine</i> , <b>1998</b> , 30, 452-9	1.5	57
12	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 257-62	5.2	3
11	Impairment of bone status in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 2275-80	5.6	21
10	Failure of long-term therapy with sodium valproate in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , <b>1997</b> , 20, 387-92	5.2	25
9	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , <b>1997</b> , 47, 23-8	3.4	77
8	Prediction of efficacy of octreotide therapy in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1996</b> , 81, 2356-62	5.6	112
7	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. <i>Clinical Endocrinology</i> , <b>1996</b> , 45, 157-66	3.4	10
6	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. <i>Gynecological Endocrinology</i> , <b>1995</b> , 9, 15-21	2.4	7
5	Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). <i>Clinical Endocrinology</i> , <b>1990</b> , 33, 161-9	3.4	32
4	L'Endocrinologo è cresciuto grazie alla sua grande squadra. <i>L'Endocrinologo</i> , 1	0	
3	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects		22
2	Early Vascular Alterations in Acromegaly		19
1	Clinical and nutritional management of very-low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: a practical guide for the nutritionist. <i>Critical Reviews in Food Science and Nutrition</i> , 1-17	11.5	1